(Q38748274)

6 September 2017

title

TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation (English)

1 reference

6 September 2017

J Kang

1

1 reference

6 September 2017

W Kim

2

1 reference

6 September 2017

S Lee

3

1 reference

6 September 2017

D Kwon

4

1 reference

6 September 2017

J Chun

5

1 reference

6 September 2017

B Son

6

1 reference

6 September 2017

E Kim

7

1 reference

6 September 2017

J-M Lee

8

1 reference

6 September 2017

H Youn

9

1 reference

6 September 2017

B Youn

10

1 reference

6 September 2017

language of work or name

English

0 references

publication date

5 September 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

36

1 reference

6 September 2017

issue

11

1 reference

6 September 2017

page(s)

1585-1596

1 reference

TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Non–Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Inhibition of Ras for cancer treatment: the search continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

The AP-2 family of transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

OncomiRs: the discovery and progress of microRNAs in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

The impact of microRNAs on protein output

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Causes and consequences of microRNA dysregulation in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Integrated molecular portrait of non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

MicroRNA signatures in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Gene expression-based classification of non-small cell lung carcinomas and survival prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

miR-33a functions as a tumor suppressor in melanoma by targeting HIF-1α.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Mir-33 regulates cell proliferation and cell cycle progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

AKAP12 induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

From cell cycle to differentiation: an expanding role for cdk6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Cyclin D as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

PAK1 tyrosine phosphorylation is required to induce epithelial-mesenchymal transition and radioresistance in lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Gene-expression profiles predict survival of patients with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Diversity of gene expression in adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Nucleophosmin acts as a novel AP2alpha-binding transcriptional corepressor during cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Sumoylation pathway is required to maintain the basal breast cancer subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

SSeCKS/Gravin/AKAP12 inhibits cancer cell invasiveness and chemotaxis by suppressing a protein kinase C- Raf/MEK/ERK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Inhibition of hedgehog signalling attenuates UVB-induced skin photoageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

[Targeting the RAS signalling pathway in cancer].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.328

A training-testing approach to the molecular classification of resected non-small cell lung cancer

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27593936

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

DANGER is involved in high glucose-induced radioresistance through inhibiting DAPK-mediated anoikis in non-small cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27593936

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2016.328

1 reference

Dimensions Publication ID

6 September 2017

1034530874

0 references

1 reference